Literature DB >> 11745638

GFRalpha-1 mRNA in dopaminergic and nondopaminergic neurons in the substantia nigra and ventral tegmental area.

A Sarabi1, B J Hoffer, L Olson, M Morales.   

Abstract

Glial cell line-derived neurotrophic factor (GDNF) is a survival factor for several types of neurons, including dopaminergic (DAergic) neurons. GDNF binds with high affinity to the GDNF family receptor alpha-1 (GFRalpha-1), which is highly expressed in the midbrain. Using anatomical and lesion techniques, we demonstrated that GFRalpha-1 was expressed in DAergic and non-DAergic neurons in the rat midbrain. Immunohistochemical characterization of GFRalpha-1-expressing neurons indicated that most of the neurons that were immunopositive for the DAergic marker tyrosine hydroxylase (TH) expressed GFRalpha-1 in the substantia nigra pars compacta (SNC). In contrast, fewer TH-containing neurons expressed GFRalpha-1 in the substantia nigra pars reticulata (SNR) and the ventral tegmental area (VTA). Depletion of GFRalpha-1/TH neurons was observed in the SNC following treatment with the neurotoxin 6-hydroxydopamine (6-OHDA); however, GFRalpha-1 expression remained in some neurons located in the SNR. The gamma-aminobutyric acid (GABA)ergic nature of GFRalpha-1-expressing neurons located in the SNR, which were resistant to (6-hydroxydopamine) 6-OHDA, was established by their expression of glutamic acid decarboxylase (GAD; the synthesizing enzyme for GABA). Further analysis indicated that coexpression of GFRalpha-1 and GAD varied in a rostrocaudal gradient in the SNR, substantia nigra pars lateralis (SNL), and VTA. Midbrain DAergic and GABAergic neurons have been previously classified according to their Ca(2+) binding protein (CaBP) content; thus, we also sought to investigate the proportion of midbrain GFRalpha-1-expressing neurons containing parvalbumin (PV), calbindin (CB), and calretinin (CR) in the midbrain. Although GFRalpha-1 expression was found mainly in CB- and CR-immunoreactive neurons, it was rarely observed in PV-immunolabeled neurons. Analysis of the proportion of GFRalpha-1-expressing neurons for each CaBP subpopulation indicated the coexistence of GFRalpha-1 with CR in the VTA and all subdivisions of the SN; double-labeled GFRalpha-1/CR neurons were distributed in the SNC, SNR, SNL, and VTA. GFRalpha-1/CB neurons were also detected in the SNC, SNL, and VTA. Expression of GFRalpha-1 in DAergic and non-DAergic neurons in the rat SN and VTA suggests that GDNF, via GFRalpha-1, might modulate DAergic and GABAergic functions in the nigrostriatal, mesolimbic, and nigrothalamic circuits of the adult rat. Published 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745638     DOI: 10.1002/cne.1400

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  22 in total

1.  Nucleus accumbens-derived glial cell line-derived neurotrophic factor is a retrograde enhancer of dopaminergic tone in the mesocorticolimbic system.

Authors:  Jun Wang; Sebastien Carnicella; Somayeh Ahmadiantehrani; Dao-Yao He; Segev Barak; Viktor Kharazia; Sami Ben Hamida; Agustin Zapata; Toni S Shippenberg; Dorit Ron
Journal:  J Neurosci       Date:  2010-10-27       Impact factor: 6.167

2.  Targeted gene transfer to nigrostriatal neurons in the rat brain by helper virus-free HSV-1 vector particles that contain either a chimeric HSV-1 glycoprotein C-GDNF or a gC-BDNF protein.

Authors:  Xiaodan Wang; Lingxin Kong; Guo-rong Zhang; Mei Sun; Alfred I Geller
Journal:  Brain Res Mol Brain Res       Date:  2005-09-13

3.  Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity.

Authors:  Bin Xing; Tao Xin; Lingling Zhao; Randy L Hunter; Yan Chen; Guoying Bing
Journal:  J Neuroimmunol       Date:  2010-05-14       Impact factor: 3.478

4.  Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption.

Authors:  Dao-Yao He; Nancy N H McGough; Ajay Ravindranathan; Jerome Jeanblanc; Marian L Logrip; Khanhky Phamluong; Patricia H Janak; Dorit Ron
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

5.  Distribution of glial cell line-derived neurotrophic factor receptor alpha-1 in the brain of adult zebrafish.

Authors:  Carla Lucini; Lucini Carla; Bruna Facello; Facello Bruna; Lucianna Maruccio; Maruccio Lucianna; Fernanda Langellotto; Langellotto Fernanda; Paolo Sordino; Sordino Paolo; Luciana Castaldo; Castaldo Luciana
Journal:  J Anat       Date:  2010-06-21       Impact factor: 2.610

6.  Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor.

Authors:  Sebastien Carnicella; Somayeh Ahmadiantehrani; Dao-Yao He; Carsten K Nielsen; Selena E Bartlett; Patricia H Janak; Dorit Ron
Journal:  Biol Psychiatry       Date:  2009-02-20       Impact factor: 13.382

7.  Nigral GFRα1 infusion in aged rats increases locomotor activity, nigral tyrosine hydroxylase, and dopamine content in synchronicity.

Authors:  Brandon S Pruett; Michael F Salvatore
Journal:  Mol Neurobiol       Date:  2013-01-16       Impact factor: 5.590

8.  Glutamatergic and nonglutamatergic neurons of the ventral tegmental area establish local synaptic contacts with dopaminergic and nondopaminergic neurons.

Authors:  Alice Dobi; Elyssa B Margolis; Hui-Ling Wang; Brandon K Harvey; Marisela Morales
Journal:  J Neurosci       Date:  2010-01-06       Impact factor: 6.167

9.  Corticotropin-releasing factor binding protein within the ventral tegmental area is expressed in a subset of dopaminergic neurons.

Authors:  Hui-Ling Wang; Marisela Morales
Journal:  J Comp Neurol       Date:  2008-07-20       Impact factor: 3.215

10.  Synapses between corticotropin-releasing factor-containing axon terminals and dopaminergic neurons in the ventral tegmental area are predominantly glutamatergic.

Authors:  Patricia Tagliaferro; Marisela Morales
Journal:  J Comp Neurol       Date:  2008-02-01       Impact factor: 3.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.